KR20010113753A - Ａ형으로 지칭되는 결정 변형의 독사조신 메실레이트의신규 제조 방법 - Google Patents

Ａ형으로 지칭되는 결정 변형의 독사조신 메실레이트의신규 제조 방법 Download PDF

Info

Publication number
KR20010113753A
KR20010113753A KR1020017011780A KR20017011780A KR20010113753A KR 20010113753 A KR20010113753 A KR 20010113753A KR 1020017011780 A KR1020017011780 A KR 1020017011780A KR 20017011780 A KR20017011780 A KR 20017011780A KR 20010113753 A KR20010113753 A KR 20010113753A
Authority
KR
South Korea
Prior art keywords
doxazosin
doxazosin mesylate
mesylate
methanol
methanesulfonic acid
Prior art date
Application number
KR1020017011780A
Other languages
English (en)
Korean (ko)
Inventor
페터 클라인
마르코 티에스
Original Assignee
독터. 호르스트 하스칼, 잉에 린스
크놀 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 독터. 호르스트 하스칼, 잉에 린스, 크놀 게엠베하 filed Critical 독터. 호르스트 하스칼, 잉에 린스
Publication of KR20010113753A publication Critical patent/KR20010113753A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020017011780A 1999-03-18 2000-03-06 Ａ형으로 지칭되는 결정 변형의 독사조신 메실레이트의신규 제조 방법 KR20010113753A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19912063A DE19912063A1 (de) 1999-03-18 1999-03-18 Neues Verfahren zur Herstellung von Doxazosin-Mesylat in einer als Form A bezeichneten Kristallmodifikation
DE19912063.3 1999-03-18
PCT/EP2000/001939 WO2000056731A1 (de) 1999-03-18 2000-03-06 Neues verfahren zur herstellung von doxazosin-mesylat in einer als form a bezeichneten kristallmodifikation

Publications (1)

Publication Number Publication Date
KR20010113753A true KR20010113753A (ko) 2001-12-28

Family

ID=7901411

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017011780A KR20010113753A (ko) 1999-03-18 2000-03-06 Ａ형으로 지칭되는 결정 변형의 독사조신 메실레이트의신규 제조 방법

Country Status (13)

Country Link
EP (1) EP1165548A1 (ja)
JP (1) JP2002540109A (ja)
KR (1) KR20010113753A (ja)
CN (1) CN1352643A (ja)
AU (1) AU3960800A (ja)
CA (1) CA2367903A1 (ja)
CZ (1) CZ20013347A3 (ja)
DE (1) DE19912063A1 (ja)
HU (1) HUP0200663A2 (ja)
IL (1) IL144944A0 (ja)
PL (1) PL350088A1 (ja)
TR (1) TR200102730T2 (ja)
WO (1) WO2000056731A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19912573A1 (de) * 1999-03-19 2000-09-21 Knoll Ag Arzneimittel, enthaltend Doxazosin-Mesylat der Kristallmodifikaton D
CA2706372A1 (en) 2007-12-24 2009-07-02 Cipla Limited Crystalline polymorph of doxazosin mesylate (form iv) and process for preparation thereof
CN109988158A (zh) * 2018-01-03 2019-07-09 合肥立方制药股份有限公司 X晶型、含有x晶型的多沙唑嗪甲磺酸盐及其制备方法和用途
CN111303130B (zh) * 2018-12-11 2021-09-14 合肥立方制药股份有限公司 一种多沙唑嗪甲磺酸盐晶型、其制备方法及用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1287588B1 (it) * 1996-12-13 1998-08-06 Alfa Chem Ital Forma cristallina del doxazosin mesilato e processo per la sua produzione
PT849266E (pt) * 1996-12-20 2007-03-30 Heumann Pcs Gmbh Nova forma polimorfa de mesilato de doxazosina (forma iii)
DE19800214A1 (de) * 1998-01-06 1999-07-15 Knoll Ag Verfahren zur Herstellung von Doxazosin-Mcsylat in einer als Form A bezeichneten Kristallmodifikation und ein Zwischenprodukt dafür

Also Published As

Publication number Publication date
PL350088A1 (en) 2002-11-04
EP1165548A1 (de) 2002-01-02
TR200102730T2 (tr) 2002-06-21
CZ20013347A3 (cs) 2002-01-16
JP2002540109A (ja) 2002-11-26
DE19912063A1 (de) 2000-09-21
IL144944A0 (en) 2002-06-30
WO2000056731A1 (de) 2000-09-28
AU3960800A (en) 2000-10-09
CN1352643A (zh) 2002-06-05
HUP0200663A2 (en) 2002-08-28
CA2367903A1 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
RU2291861C2 (ru) Способ получения производных хинолина
FI82189C (fi) Foerfarande foer framstaellning av en stabil modifikation av torasemid.
KR20120139763A (ko) 랄테그라비어 염 및 이의 결정형
JP2004500324A (ja) ピペラジン環含有化合物の新規の合成及び結晶化
KR20010113753A (ko) Ａ형으로 지칭되는 결정 변형의 독사조신 메실레이트의신규 제조 방법
US6130218A (en) Polymorphic form of doxazosin mesylate (Form I)
US20090012296A1 (en) Processes for the preparation of crystalline form beta of imatinib mesylate
WO2017177781A1 (zh) Ahu377的晶型及其制备方法与用途
US6500830B1 (en) Conversion of modification D to modification A of doxazosin mesylate
RU2228931C2 (ru) Кристаллические формы 3-(2,4-дихлорбензил)-2-метил-n-(пентилсульфонил)-3h- бензимидазол-5-карбоксамида
KR100659927B1 (ko) 다형태를갖는독사조신메실레이트의새로운형태(제iii형)
US6133269A (en) Polymorphic form of doxazosin mesylate (form II)
US20070167494A1 (en) Process for preparing a polymorph or rosiglitazone maleate
EA008055B1 (ru) Кристаллические формы оланзапина и способы их получения
CN102336701A (zh) 硫酸卡维地洛的结晶、其制备方法及其在医药上的应用
RU2130456C1 (ru) СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ МОНОГИДРАТНОЙ ФОРМЫ β-ЛАКТАМА
WO2021119223A1 (en) Solid state form of lemborexant
CN112028838B (zh) 一种2-乙氧基-5-氟尿嘧啶杂质的制备方法
EP1730153B1 (en) Isopropanol water solvate of olanzapine
US5677463A (en) Process for the preparation of 2-imino-5-phenyl-4 oxazolidinone and its intermediates
WO2004089904A2 (en) Preparation of torasemide
TW202227387A (zh) 單水合曲前列環素晶體及其製備方法
CN108658952B (zh) 维拉佐酮盐酸盐iv型结晶的制备方法
CN117209454A (zh) 一种左西替利嗪钠新晶型及其制备方法
CN112409350A (zh) 一种马来酸阿伐曲泊帕晶型c的制备方法

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid